Johnson & Johnson: Multiple Myeloma trials

The registry lists 123 Multiple Myeloma studies with Johnson & Johnson as lead sponsor. 14 are open to participants now and 34 have results posted.

Phase 1 27Phase 2 37Phase 3 34Phase 4 4No phase 26(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not PlannedRecruitingNCT07665450Phase 3
• A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple MyelomaRecruitingNCT07589634Phase 2
• A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Phase 3
• A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07258511Phase 3
• A Study to Evaluate Efficacy and Safety of Ciltacabtagene AutoleucelRecruitingNCT07149857Phase 2
• A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple MyelomaRecruitingNCT06768489Phase 1
• A Study to Evaluate Preventive Treatments for GPRC5D-related Oral EventsRecruitingNCT06500884Phase 2
• A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical TrialsRecruitingNCT06285318
• A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) AmyloidosisRecruitingNCT05652335Phase 1
• A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Phase 3
• Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple MyelomaAvailableNCT05346835
• A Long-term Study for Participants Previously Treated With Ciltacabtagene AutoleucelRecruitingNCT05201781Phase 4
• A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT05160584
• A Study of Talquetamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT04634552Phase 2
• A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple MyelomaCompletedNCT05347485Phase 2Results posted
• A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple MyelomaActive, not recruitingNCT04181827Phase 3Results posted
• A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell TransplantCompletedNCT03901963Phase 3Results posted
• Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With DaratumumabTerminatedNCT03871829Phase 2Results posted
• A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial TherapyCompletedNCT03652064Phase 3Results posted
• A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03548207Phase 1/2Results posted
• A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment RegimensCompletedNCT03412565Phase 2Results posted
• A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03357952Phase 2/3Results posted
• A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03277105Phase 3Results posted
• A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple MyelomaCompletedNCT02951819Phase 2Results posted
• Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple MyelomaCompletedNCT02874742Phase 2Results posted
• A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple MyelomaCompletedNCT02316106Phase 2Results posted
• Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple MyelomaCompletedNCT02252172Phase 3Results posted
• A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple MyelomaCompletedNCT02195479Phase 3Results posted
• Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT02136134Phase 3Results posted
• A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaCompletedNCT02076009Phase 3Results posted
• An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiDCompletedNCT01985126Phase 2Results posted
• A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple MyelomaCompletedNCT01801436Phase 3Results posted
• Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple MyelomaCompletedNCT01615029Phase 1/2Results posted
• Velcade (Bortezomib) Consolidation After TransplantCompletedNCT01539083Phase 3Results posted
• A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple MyelomaCompletedNCT01484275Phase 2Results posted
• Velcade Consolidation Bone StudyCompletedNCT01286077Phase 2Results posted
• A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)CompletedNCT00985959Phase 1Results posted
• A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma PatientsCompletedNCT00911859Phase 2Results posted
• Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VDCompletedNCT00908232Phase 2Results posted
• A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple MyelomaCompletedNCT00872521Phase 2Results posted
• A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose ChemotherapyCompletedNCT00833560Phase 2Results posted
• Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple MyelomaCompletedNCT00813150Phase 3Results posted
• An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney FunctionTerminatedNCT00718640Phase 2Results posted
• Daratumumab (HuMax®-CD38) Safety Study in Multiple MyelomaCompletedNCT00574288Phase 2Results posted
• Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple MyelomaTerminatedNCT00441168Phase 2Results posted
• A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00401843Phase 2Results posted
• Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple MyelomaCompletedNCT00103506Phase 3Results posted
• A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00097981Phase 3Results posted
• A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT07266441Phase 2
• A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple MyelomaActive, not recruitingNCT07030517Phase 4
• A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06604715Phase 1
• A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple MyelomaActive, not recruitingNCT06577025Phase 2
• A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple MyelomaActive, not recruitingNCT06550895Phase 2
• A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06425991Phase 1
• A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Phase 3
• Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple MyelomaApproved for marketingNCT05757973
• A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Phase 3
• Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple MyelomaNo longer availableNCT05503550
• Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma PatientsApproved for marketingNCT05463939
• A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentActive, not recruitingNCT05455320Phase 3
• A Study of DaratumumabActive, not recruitingNCT05438043Phase 3
• Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)No longer availableNCT05161598
• A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Phase 3
• A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple MyelomaActive, not recruitingNCT05050097Phase 1
• A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial TherapyActive, not recruitingNCT04923893Phase 3
• A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT04773522Phase 1
• A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple MyelomaActive, not recruitingNCT04722146Phase 1
• A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04586426Phase 1/2
• Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple MyelomaNo longer availableNCT04452994
• A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple MyelomaActive, not recruitingNCT04133636Phase 2
• A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple MyelomaCompletedNCT04121260Phase 1
• A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple MyelomaActive, not recruitingNCT04108195Phase 1
• A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody TreatmentCompletedNCT04035226
• A Registry Study of Participants With Multiple Myeloma in Latin AmericaCompletedNCT03955900
• A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory AgentCompletedNCT03768960Phase 4
• A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03242889Phase 1
• A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Phase 3
• A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Phase 3
• Multiple Myeloma Patient RegistryTerminatedNCT03180853
• A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell TransplantationCompletedNCT02918331Phase 1
• Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic TherapyCompletedNCT02852837Phase 1
• Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT02811978Phase 3
• Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin AmericaCompletedNCT02559583
• A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT02519452Phase 1
• A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT02497378Phase 1
• Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple MyelomaApproved for marketingNCT02477891
• Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple MyelomaCompletedNCT02474563
• A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple MyelomaCompletedNCT02268890Phase 4
• A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT02116569Phase 1
• A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple MyelomaCompletedNCT01998971Phase 1
• Study to Evaluate Optimized Retreatment and Prolonged Therapy With BortezomibCompletedNCT01910987Phase 3
• An Observational Study of Chinese Multiple Myeloma Patients Treated With VelcadeCompletedNCT01675245
• Retrospective Survey of Re-treatment With BortezomibCompletedNCT01524445
• A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple MyelomaCompletedNCT01464112Phase 1
• A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple MyelomaCompletedNCT01371227Phase 1
• A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple MyelomaTerminatedNCT01309412Phase 1
• A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaWithdrawnNCT01266811Phase 3
• A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any ProcedureCompletedNCT01241396
• A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple MyelomaCompletedNCT01219010Phase 1
• Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early BortezomibCompletedNCT01060202